Barclays PLC Grows Position in Fractyl Health, Inc. (NASDAQ:GUTS)

Barclays PLC lifted its holdings in shares of Fractyl Health, Inc. (NASDAQ:GUTS) by 1,754.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 47,796 shares of the company’s stock after purchasing an additional 45,219 shares during the quarter. Barclays PLC owned 0.10% of Fractyl Health worth $121,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of GUTS. Rhumbline Advisers bought a new stake in Fractyl Health during the second quarter valued at approximately $32,000. Renaissance Technologies LLC purchased a new stake in shares of Fractyl Health during the 2nd quarter valued at $61,000. SG Americas Securities LLC bought a new stake in shares of Fractyl Health during the 3rd quarter worth $33,000. Beta Wealth Group Inc. purchased a new position in Fractyl Health in the third quarter worth $44,000. Finally, Massachusetts Financial Services Co. MA grew its position in Fractyl Health by 4.9% in the third quarter. Massachusetts Financial Services Co. MA now owns 1,045,672 shares of the company’s stock worth $2,646,000 after acquiring an additional 49,289 shares in the last quarter.

Fractyl Health Trading Up 9.0 %

NASDAQ GUTS opened at $2.05 on Friday. The company has a quick ratio of 5.57, a current ratio of 5.58 and a debt-to-equity ratio of 0.60. The stock’s 50-day simple moving average is $2.07 and its two-hundred day simple moving average is $2.65. Fractyl Health, Inc. has a twelve month low of $1.74 and a twelve month high of $14.50. The company has a market capitalization of $98.61 million and a price-to-earnings ratio of -0.17.

Fractyl Health (NASDAQ:GUTS) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.48) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.02. The firm had revenue of $0.01 million for the quarter. Research analysts forecast that Fractyl Health, Inc. will post -1.66 EPS for the current fiscal year.

Insiders Place Their Bets

In other Fractyl Health news, insider Jay David Caplan sold 64,197 shares of the company’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $2.47, for a total transaction of $158,566.59. Following the completion of the sale, the insider now directly owns 153,544 shares in the company, valued at $379,253.68. This represents a 29.48 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Harith Rajagopalan sold 96,517 shares of the firm’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $2.47, for a total value of $238,396.99. Following the transaction, the chief executive officer now directly owns 491,329 shares in the company, valued at $1,213,582.63. This trade represents a 16.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here.

Fractyl Health Company Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.